A Phase 2 interventional study of Vamikibart and Ranibizumab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 74 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 2, and was the 17th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 14 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 377 across the 25 interventional studies, 736 across the 3 observational. Of the 23 that completed or were terminated, 17 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Macular Edema by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vamikibart 0.25 milligrams (mg), by intravitreal (IVT) injection, on Day 1 and every 8th week (Q8W), up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
Drug: Vamikibart · Other: Sham Procedure
Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and Q8W, up to Week 44, for a total of 6 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
Drug: Vamikibart · Other: Sham Procedure
Participants will receive vamikibart 1.0 mg, by IVT injection, on Day 1 and every 4th week (Q4W), up to Week 44 for a total of 12 injections.
Drug: Vamikibart
Participants will receive ranibizumab 0.5 mg, by IVT injection, on Day 1 and Q4W, up to Week 44 for a total of 12 injections.
Drug: Ranibizumab
Vamikibart will be administered by IVT injection as specified in each treatment arm.
Also known as: RO7200220
Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
Also known as: Lucentis
Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants
The BCVA, at a starting test distance of 4 meters (m), was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified early treatment diabetic retinopathy study \[ETDRS\] charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 44 and 48
Number of Participants With Systemic and Ocular Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs. Only one eye was selected as the study eye, while the other was referred to as the fellow eye.
Time frame: Up to Week 72
Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 44 and 48
Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 44 and 48
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 32 and 36
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 32 and 36
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 32 and 36
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 20 and 24
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 20 and 24
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 20 and 24
Change From Baseline in BCVA Over Time, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72
Percentage of Participants Gaining Greater Than or Equal to (≥) 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
Time frame: From baseline up to Week 72
Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA From Baseline Over Time, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
Time frame: From baseline up to Week 72
Percentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Percentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Percentage of Participants With BCVA of Less Than or Equal to (≤) 38 Letters (Snellen Equivalent 20/200) Over Time, in Overall Enrolled Population
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Change From Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44 and 48, in Treatment-naïve Participants
CST was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE), measured using Spectral Domain-Optical Coherence Tomography (SD-OCT). This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 44 and 48
Change From Baseline in CST Averaged Over Weeks 44 and 48, in Previously Treated Participants
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 44 and 48
Change From Baseline in CST Averaged Over Weeks 44 and 48, in Overall Enrolled Population
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 44 and 48
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Treatment-naïve Participants
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 32 and 36
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Previously Treated Participants
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 32 and 36
Change From Baseline in CST Averaged Over Weeks 32 and 36, in Overall Enrolled Population
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 32 and 36
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Treatment-naïve Participants
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 20 and 24
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Previously Treated Participants
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 20 and 24
Change From Baseline in CST Averaged Over Weeks 20 and 24, in Overall Enrolled Population
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 20 and 24
Change From Baseline in CST Over Time, in Overall Enrolled Population
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72
Percentage of Participants With Absence of DME Over Time, in Overall Enrolled Population
Absence of DME was defined as CST \< 325 µm for spectralis SD-OCT, or \< 315 μm for cirrus SD-OCT or topcon SD-OCT. SD-OCT was performed on a Spectralis instrument. Percentages have been summarized.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72
Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time, in Overall Enrolled Population
The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with the absence of IRF at the foveal center were reported. Percentages have been summarized.
Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72
Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time, in Overall ITT Population
The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center were reported. Percentages have been summarized.
Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72
A total of 394 participants with diabetic macular edema (DME) took part in the study at 74 investigative sites across Argentina, Canada, Czech Republic, Spain, Republic of Korea, Poland, the United Kingdom and the United States from 31 December 2021 to 21 April 2025.
| Milestone | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Started | 95 | 101 | 98 | 100 |
| Safety-evaluable population | 94 | 100 | 98 | 98 |
| Treatment-naïve intent-to-treat (itt) population | 65 | 65 | 64 | 65 |
| Previously treated itt population | 30 | 36 | 34 | 35 |
| Completed | 57 | 64 | 64 | 84 |
| Not completed | 38 | 37 | 34 | 16 |
| Withdrew: Adverse event | 8 | 9 | 9 | 3 |
| Withdrew: Death | 1 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 1 | 4 | 3 |
| Withdrew: Need for rescue treatment | 11 | 10 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 1 |
| Withdrew: Reason not specified | 6 | 11 | 6 | 2 |
| Withdrew: Physician decision | 1 | 2 | 4 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 6 | 6 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs. Only one eye was selected as the study eye, while the other was referred to as the fellow eye.
| Participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Systemic AEs | 43 | 58 | 54 | 65 |
| Ocular AEs in Study Eye | 39 | 46 | 41 | 31 |
| Ocular AEs in Fellow Eye | 13 | 25 | 24 | 29 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Previously Treated Participants | 2.0 ± 2.74 | -0.5 ± 2.39 | -0.4 ± 2.49 | 9.6 ± 2.21 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 44 and Week 48, in Overall Enrolled Population | 5.2 ± 1.19 | 3.3 ± 1.13 | 3.8 ± 1.16 | 11.7 ± 1.09 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants | 5.8 ± 1.24 | 3.4 ± 1.23 | 5.8 ± 1.26 | 13.0 ± 1.23 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants | 2.0 ± 1.31 | 3.4 ± 1.14 | 4.4 ± 1.20 | 8.5 ± 1.12 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall Enrolled Population | 4.4 ± 0.93 | 3.6 ± 0.88 | 5.5 ± 0.91 | 11.4 ± 0.88 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Treatment-naïve Participants | 6.4 ± 1.19 | 3.5 ± 1.18 | 5.3 ± 1.20 | 11.1 ± 1.19 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Previously Treated Participants | 2.7 ± 1.36 | 2.8 ± 1.19 | 5.4 ± 1.22 | 8.4 ± 1.18 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall Enrolled Population | 5.1 ± 0.92 | 3.3 ± 0.87 | 5.4 ± 0.89 | 10.2 ± 0.88 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a MMRM model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change at Week 4 | 3.0 ± 0.65 | 2.3 ± 0.63 | 3.8 ± 0.64 | 6.2 ± 0.63 |
| Change at Week 8 | 4.3 ± 0.68 | 3.3 ± 0.65 | 5.1 ± 0.66 | 7.6 ± 0.66 |
| Change at Week 12 | 4.4 ± 0.87 | 4.2 ± 0.82 | 4.6 ± 0.84 | 8.2 ± 0.83 |
| Change at Week 16 | 4.5 ± 0.85 | 3.7 ± 0.81 | 5.0 ± 0.83 | 9.1 ± 0.83 |
| Change at Week 20 | 5.2 ± 0.98 | 3.5 ± 0.92 | 5.0 ± 0.95 | 10.2 ± 0.93 |
| Change at Week 24 | 5.0 ± 0.93 | 3.2 ± 0.88 | 5.9 ± 0.90 | 10.3 ± 0.89 |
| Change at Week 28 | 4.6 ± 0.95 | 3.1 ± 0.90 | 5.3 ± 0.93 | 10.6 ± 0.91 |
| Change at Week 32 | 4.5 ± 0.95 | 3.4 ± 0.90 | 5.8 ± 0.94 | 11.3 ± 0.90 |
| Change at Week 36 | 4.2 ± 0.98 | 3.6 ± 0.92 | 5.2 ± 0.96 | 11.4 ± 0.92 |
| Change at Week 40 | 4.7 ± 1.25 | 2.3 ± 1.19 | 4.5 ± 1.22 | 11.8 ± 1.14 |
| Change at Week 44 | 5.3 ± 1.22 | 3.5 ± 1.16 | 4.3 ± 1.19 | 11.7 ± 1.12 |
| Change at Week 48 | 4.9 ± 1.22 | 2.9 ± 1.16 | 3.2 ± 1.19 | 11.5 ± 1.11 |
| Change at Week 52 | 4.8 ± 1.11 | 4.1 ± 1.05 | 4.7 ± 1.07 | 10.4 ± 1.01 |
| Change at Week 56 | 4.3 ± 1.34 | 2.5 ± 1.26 | 4.1 ± 1.30 | 9.8 ± 1.20 |
| Change at Week 60 | 4.3 ± 1.41 | 3.5 ± 1.32 | 3.3 ± 1.37 | 8.8 ± 1.25 |
| Change at Week 64 | 4.8 ± 1.45 | 3.7 ± 1.35 | 2.4 ± 1.40 | 9.2 ± 1.30 |
| Change at Week 68 | 5.6 ± 1.36 | 4.2 ± 1.28 | 2.9 ± 1.32 | 9.7 ± 1.22 |
| Change at Week 72 | 4.5 ± 1.39 | 3.6 ± 1.29 | 2.9 ± 1.35 | 9.2 ± 1.24 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Participants gaining ≥ 0 Letters | 97.9 | 98.0 | 99.0 | 100 |
| Participants gaining ≥ 5 Letters | 79.8 | 83.0 | 76.5 | 94.9 |
| Participants gaining ≥ 10 Letters | 51.1 | 60.0 | 56.1 | 75.5 |
| Participants gaining ≥ 15 Letters | 26.6 | 28.0 | 34.7 | 58.2 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Participants avoiding a loss of ≥ 5 Letters | 70.2 | 61.0 | 64.3 | 83.7 |
| Participants avoiding a loss of ≥ 10 Letters | 85.1 | 80.0 | 87.8 | 93.9 |
| Participants avoiding a loss of ≥ 15 Letters | 92.6 | 87.0 | 89.8 | 95.9 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Baseline | 34.7 | 32.7 | 43.9 | 35.0 |
| Week 1 | 45.6 | 44.3 | 53.7 | 53.6 |
| Week 4 | 50.6 | 49.5 | 55.3 | 65.6 |
| Week 8 | 56.5 | 46.9 | 63.3 | 73.1 |
| Week 12 | 59.0 | 51.0 | 63.2 | 78.3 |
| Week 16 | 57.8 | 52.2 | 61.8 | 77.3 |
| Week 20 | 62.8 | 50.5 | 61.4 | 79.1 |
| Week 24 | 64.5 | 52.9 | 65.0 | 83.5 |
| Week 28 | 63.5 | 52.9 | 68.9 | 77.4 |
| Week 32 | 71.0 | 51.9 | 67.2 | 81.6 |
| Week 36 | 65.2 | 53.8 | 66.7 | 84.3 |
| Week 40 | 64.6 | 57.1 | 72.1 | 81.7 |
| Week 44 | 68.8 | 62.0 | 69.7 | 84.0 |
| Week 48 | 67.8 | 62.7 | 57.6 | 84.3 |
| Week 52 | 66.0 | 61.3 | 65.6 | 75.6 |
| Week 56 | 78.7 | 60.0 | 73.6 | 77.6 |
| Week 60 | 67.4 | 58.2 | 76.0 | 80.6 |
| Week 64 | 75.6 | 57.4 | 72.9 | 83.3 |
| Week 68 | 70.0 | 58.3 | 65.9 | 84.9 |
| Week 72 | 67.6 | 66.0 | 74.4 | 83.0 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Baseline | 1.1 | 1.0 | 0 | 1.0 |
| Week 1 | 2.2 | 0 | 0 | 6.2 |
| Week 4 | 4.5 | 0 | 4.3 | 3.1 |
| Week 8 | 3.5 | 5.2 | 5.6 | 5.4 |
| Week 12 | 6.4 | 2.1 | 8.0 | 6.5 |
| Week 16 | 7.2 | 3.3 | 11.2 | 9.1 |
| Week 20 | 5.1 | 7.7 | 12.0 | 14.3 |
| Week 24 | 7.9 | 4.7 | 12.5 | 15.3 |
| Week 28 | 5.4 | 7.1 | 8.1 | 14.3 |
| Week 32 | 10.1 | 8.9 | 10.4 | 20.7 |
| Week 36 | 5.8 | 10.0 | 8.7 | 15.7 |
| Week 40 | 7.7 | 10.0 | 11.8 | 19.5 |
| Week 44 | 12.5 | 12.7 | 12.1 | 21.0 |
| Week 48 | 6.8 | 9.0 | 12.1 | 16.9 |
| Week 52 | 5.7 | 14.5 | 17.2 | 19.5 |
| Week 56 | 10.6 | 11.7 | 18.9 | 18.4 |
| Week 60 | 13.0 | 12.7 | 18.0 | 20.9 |
| Week 64 | 17.1 | 11.1 | 18.8 | 22.2 |
| Week 68 | 15.0 | 12.5 | 15.9 | 26.4 |
| Week 72 | 13.5 | 12.8 | 17.9 | 25.5 |
The BCVA, at a starting test distance of 4 m, was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified ETDRS charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. A gain in BCVA letter score from baseline indicates an improvement in visual acuity. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Baseline | 1.1 | 1.0 | 1.0 | 1.0 |
| Week 1 | 2.2 | 3.1 | 1.1 | 0 |
| Week 4 | 1.1 | 2.1 | 1.1 | 0 |
| Week 8 | 1.2 | 1.0 | 0 | 0 |
| Week 12 | 1.3 | 1.0 | 1.1 | 0 |
| Week 16 | 1.2 | 1.1 | 2.2 | 1.1 |
| Week 20 | 1.3 | 3.3 | 3.6 | 0 |
| Week 24 | 1.3 | 2.4 | 1.3 | 0 |
| Week 28 | 0 | 2.4 | 1.4 | 0 |
| Week 32 | 0 | 1.3 | 1.5 | 0 |
| Week 36 | 0 | 1.3 | 2.9 | 0 |
| Week 40 | 0 | 1.4 | 4.4 | 0 |
| Week 44 | 0 | 0 | 3.0 | 0 |
| Week 48 | 1.7 | 1.5 | 3.0 | 0 |
| Week 52 | 3.8 | 0 | 1.6 | 0 |
| Week 56 | 0 | 1.7 | 3.8 | 0 |
| Week 60 | 0 | 1.8 | 4.0 | 0 |
| Week 64 | 0 | 1.9 | 4.2 | 0 |
| Week 68 | 0 | 2.1 | 2.3 | 0 |
| Week 72 | 0 | 2.1 | 5.1 | 0 |
CST was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE), measured using Spectral Domain-Optical Coherence Tomography (SD-OCT). This analysis used a MMRM model. Adjusted mean has been reported.
| micrometers (µm) | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in Central Subfield Thickness (CST) Averaged Over Weeks 44 and 48, in Treatment-naïve Participants | -68.4 ± 14.23 | -50.8 ± 14.18 | -67.5 ± 14.44 | -174.2 ± 13.95 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 44 and 48, in Previously Treated Participants | -40.9 ± 22.14 | -81.4 ± 19.39 | -75.8 ± 20.44 | -185.7 ± 18.54 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 44 and 48, in Overall Enrolled Population | -57.3 ± 12.14 | -61.1 ± 11.64 | -70.5 ± 11.97 | -176.9 ± 11.32 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 32 and 36, in Treatment-naïve Participants | -57.1 ± 14.02 | -46.9 ± 13.94 | -64.8 ± 14.22 | -163.9 ± 13.87 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 32 and 36, in Previously Treated Participants | -35.4 ± 19.87 | -90.5 ± 17.45 | -81.5 ± 18.34 | -168.5 ± 17.10 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 32 and 36, in Overall Enrolled Population | -47.6 ± 11.57 | -62.1 ± 11.09 | -69.4 ± 11.41 | -164.8 ± 10.95 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 20 and 24, in Treatment-naïve Participants | -48.5 ± 11.61 | -68.8 ± 11.53 | -68.5 ± 11.62 | -150.4 ± 11.56 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 20 and 24, in Previously Treated Participants | -5.7 ± 20.88 | -81.7 ± 18.67 | -68.7 ± 19.22 | -146.4 ± 18.47 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in CST Averaged Over Weeks 20 and 24, in Overall Enrolled Population | -36.1 ± 10.28 | -72.9 ± 9.88 | -69.0 ± 10.01 | -148.1 ± 9.86 |
CST was defined as the distance between the ILM and the RPE, measured using SD-OCT. This analysis used a MMRM model. Adjusted mean has been reported.
| µm | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change at Week 4 | -25.7 ± 8.06 | -26.6 ± 7.88 | -36.3 ± 7.93 | -106.9 ± 7.83 |
| Change at Week 8 | -31.2 ± 9.02 | -34.0 ± 8.76 | -50.9 ± 8.87 | -130.7 ± 8.76 |
| Change at Week 12 | -38.4 ± 9.66 | -52.9 ± 9.27 | -56.3 ± 9.41 | -131.4 ± 9.27 |
| Change at Week 16 | -39.3 ± 10.43 | -55.0 ± 10.06 | -59.5 ± 10.16 | -138.8 ± 10.08 |
| Change at Week 20 | -37.9 ± 10.88 | -71.5 ± 10.44 | -64.0 ± 10.59 | -139.9 ± 10.41 |
| Change at Week 24 | -30.7 ± 10.73 | -71.4 ± 10.31 | -69.7 ± 10.46 | -152.4 ± 10.27 |
| Change at Week 28 | -47.3 ± 11.36 | -66.7 ± 10.87 | -67.3 ± 11.14 | -158.9 ± 10.81 |
| Change at Week 32 | -47.2 ± 11.82 | -59.6 ± 11.33 | -69.6 ± 11.66 | -159.2 ± 11.18 |
| Change at Week 36 | -44.2 ± 12.07 | -61.6 ± 11.56 | -64.8 ± 11.93 | -166.8 ± 11.40 |
| Change at Week 40 | -50.3 ± 12.51 | -56.1 ± 12.03 | -69.7 ± 12.34 | -164.2 ± 11.74 |
| Change at Week 44 | -53.5 ± 12.26 | -56.4 ± 11.75 | -73.6 ± 12.11 | -174.4 ± 11.44 |
| Change at Week 48 | -58.4 ± 12.76 | -62.2 ± 12.24 | -63.1 ± 12.52 | -176.2 ± 11.82 |
| Change at Week 52 | -63.4 ± 13.52 | -72.0 ± 12.89 | -89.6 ± 13.01 | -112.4 ± 11.92 |
| Change at Week 56 | -67.6 ± 14.94 | -81.6 ± 13.84 | -74.6 ± 14.36 | -107.3 ± 12.66 |
| Change at Week 60 | -73.9 ± 14.17 | -77.2 ± 13.41 | -81.5 ± 13.69 | -111.0 ± 12.34 |
| Change at Week 64 | -66.1 ± 14.20 | -66.3 ± 13.31 | -81.1 ± 13.65 | -112.5 ± 12.48 |
| Change at Week 68 | -73.2 ± 14.64 | -88.8 ± 13.81 | -65.4 ± 14.13 | -115.2 ± 12.87 |
| Change at Week 72 | -73.9 ± 14.28 | -81.9 ± 13.45 | -78.8 ± 13.83 | -113.1 ± 12.61 |
Absence of DME was defined as CST \< 325 µm for spectralis SD-OCT, or \< 315 μm for cirrus SD-OCT or topcon SD-OCT. SD-OCT was performed on a Spectralis instrument. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Baseline | 3.2 (0.0 to 6.7) | 1.0 (0.0 to 3.0) | 4.1 (0.2 to 8.1) | 6.0 (1.3 to 10.7) |
| Week 4 | 6.8 (1.6 to 12.1) | 8.4 (2.8 to 14.0) | 13.8 (6.9 to 20.8) | 35.4 (25.8 to 45.0) |
| Week 8 | 10.6 (4.0 to 17.1) | 12.5 (5.9 to 19.1) | 17.8 (9.9 to 25.7) | 53.3 (43.1 to 63.5) |
| Week 12 | 8.9 (2.6 to 15.1) | 18.9 (11.1 to 26.8) | 24.1 (15.1 to 33.1) | 53.3 (43.1 to 63.5) |
| Week 16 | 12.0 (5.0 to 19.1) | 16.3 (8.8 to 23.9) | 25.8 (16.7 to 34.9) | 61.4 (51.2 to 71.5) |
| Week 20 | 19.2 (10.5 to 28.0) | 27.8 (18.5 to 37.0) | 30.1 (20.3 to 40.0) | 64.4 (54.6 to 74.3) |
| Week 24 | 17.1 (8.6 to 25.6) | 25.9 (16.6 to 35.2) | 26.3 (16.6 to 35.9) | 70.6 (60.9 to 80.3) |
| Week 28 | 24.7 (14.8 to 34.5) | 29.4 (19.7 to 39.1) | 33.8 (23.0 to 44.6) | 73.8 (64.4 to 83.2) |
| Week 32 | 35.7 (24.5 to 46.9) | 28.8 (18.8 to 38.7) | 34.3 (23.0 to 45.7) | 75.9 (66.9 to 84.9) |
| Week 36 | 30.0 (19.3 to 40.7) | 31.3 (21.1 to 41.4) | 35.3 (23.9 to 46.7) | 79.5 (70.8 to 88.2) |
| Week 40 | 33.3 (22.0 to 44.7) | 27.1 (16.7 to 37.6) | 35.3 (23.9 to 46.7) | 78.0 (69.1 to 87.0) |
| Week 44 | 34.4 (22.7 to 46.0) | 33.8 (22.8 to 44.8) | 35.4 (23.8 to 47.0) | 80.2 (71.6 to 88.9) |
| Week 48 | 41.7 (29.2 to 54.1) | 35.8 (24.3 to 47.3) | 30.8 (19.5 to 42.0) | 79.5 (70.8 to 88.2) |
| Week 52 | 35.8 (22.9 to 48.8) | 39.3 (27.1 to 51.6) | 36.5 (24.6 to 48.4) | 54.9 (44.1 to 65.6) |
| Week 56 | 36.2 (22.4 to 49.9) | 41.7 (29.2 to 54.1) | 45.3 (31.9 to 58.7) | 59.7 (48.8 to 70.7) |
| Week 60 | 47.8 (33.4 to 62.3) | 41.8 (28.8 to 54.9) | 50.0 (36.1 to 63.9) | 61.2 (49.5 to 72.9) |
| Week 64 | 48.8 (33.5 to 64.1) | 48.1 (34.8 to 61.5) | 47.9 (33.8 to 62.0) | 61.8 (49.0 to 74.7) |
| Week 68 | 45.0 (29.6 to 60.4) | 51.1 (36.8 to 65.4) | 48.8 (33.9 to 63.8) | 62.3 (49.2 to 75.3) |
| Week 72 | 43.2 (27.3 to 59.2) | 42.6 (28.4 to 56.7) | 48.7 (33.0 to 64.4) | 60.9 (46.8 to 75.0) |
The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with the absence of IRF at the foveal center were reported. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Baseline | 22.1 | 15.2 | 24.7 | 25.0 |
| Week 4 | 21.6 | 26.6 | 32.3 | 46.9 |
| Week 12 | 33.8 | 40.0 | 38.1 | 56.0 |
| Week 24 | 34.7 | 45.2 | 53.8 | 64.3 |
| Week 36 | 42.4 | 43.6 | 43.9 | 84.0 |
| Week 48 | 49.2 | 47.8 | 44.4 | 77.8 |
| Week 72 | 62.2 | 55.3 | 61.5 | 76.1 |
The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center were reported. Percentages have been summarized.
| percentage of participants | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Baseline | 62.1 | 61.6 | 68.0 | 67.0 |
| Week 4 | 70.5 | 71.6 | 82.8 | 85.4 |
| Week 12 | 81.8 | 77.9 | 87.1 | 96.7 |
| Week 24 | 84.0 | 89.3 | 88.6 | 97.6 |
| Week 36 | 87.9 | 89.7 | 93.9 | 100 |
| Week 48 | 89.8 | 91.0 | 93.7 | 98.8 |
| Week 72 | 94.6 | 93.6 | 97.4 | 95.7 |
The BCVA, at a starting test distance of 4 meters (m), was measured for both eyes, prior to dilating eyes by using the set of three Precision visionTM or Lighthouse distance acuity charts (modified early treatment diabetic retinopathy study \[ETDRS\] charts 1, 2 and R) by trained and certified personnel at the study sites and at each study visit. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean has been reported.
| ETDRS letters | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants | 7.1 ± 1.28 | 4.6 ± 1.26 | 5.5 ± 1.29 | 13.0 ± 1.26 |
Collected over From baseline up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Vamikibart 0.25 mg Q8W | 1/94 (1.1%) | 17/94 (18.1%) | 25/94 (26.6%) |
| Arm B: Vamikibart 1 mg Q8W | 1/100 (1%) | 25/100 (25%) | 40/100 (40%) |
| Arm C: Vamikibart 1 mg Q4W | 1/98 (1%) | 21/98 (21.4%) | 36/98 (36.7%) |
| Arm D: Ranibizumab 0.5 mg Q4W | 1/98 (1%) | 20/98 (20.4%) | 32/98 (32.7%) |
| Event | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/94 | 4/100 | 1/98 | 1/98 |
| UveitisEye disorders | 0/94 | 1/100 | 3/98 | 0/98 |
| Cerebrovascular accidentNervous system disorders | 0/94 | 2/100 | 3/98 | 0/98 |
| Vitreous haemorrhageEye disorders | 0/94 | 3/100 | 1/98 | 2/98 |
| Myocardial infarctionCardiac disorders | 2/94 | 0/100 | 0/98 | 0/98 |
| Retinal occlusive vasculitisEye disorders | 0/94 | 0/100 | 2/98 | 0/98 |
| Urinary tract infectionInfections and infestations | 0/94 | 2/100 | 0/98 | 2/98 |
| Chronic kidney diseaseRenal and urinary disorders | 0/94 | 1/100 | 2/98 | 0/98 |
| End stage renal diseaseRenal and urinary disorders | 0/94 | 0/100 | 2/98 | 0/98 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/94 | 0/100 | 0/98 | 2/98 |
| Event | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W |
|---|---|---|---|---|
| Diabetic retinal oedemaEye disorders | 7/94 | 10/100 | 12/98 | 5/98 |
| Conjunctival haemorrhageEye disorders | 6/94 | 10/100 | 6/98 | 6/98 |
| CataractEye disorders | 1/94 | 7/100 | 5/98 | 9/98 |
| HypertensionVascular disorders | 6/94 | 8/100 | 5/98 | 7/98 |
| Vitreous haemorrhageEye disorders | 3/94 | 6/100 | 6/98 | 4/98 |
| COVID-19Infections and infestations | 2/94 | 6/100 | 3/98 | 4/98 |
| Diabetic retinopathyEye disorders | 5/94 | 2/100 | 4/98 | 2/98 |
| NasopharyngitisInfections and infestations | 2/94 | 2/100 | 4/98 | 5/98 |
Overall intent-to-treat (ITT) population included all randomized participants. Participants were grouped according to the treatment assigned at randomization.
| Age, Continuous(years) | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W | Total |
|---|---|---|---|---|---|
| Mean | 64.2 ± 9.8 | 63.2 ± 10.0 | 62.8 ± 8.7 | 59.8 ± 9.8 | 62.5 ± 9.7 |
| Sex: Female, Male(Participants) | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W | Total |
|---|---|---|---|---|---|
| Female | 51 | 45 | 43 | 45 | 184 |
| Male | 44 | 56 | 55 | 55 | 210 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 15 | 14 | 10 | 8 | 47 |
| Not Hispanic or Latino | 42 | 47 | 54 | 55 | 198 |
| Unknown or Not Reported | 38 | 40 | 34 | 37 | 149 |
| Race (NIH/OMB)(Participants) | Arm A: Vamikibart 0.25 mg Q8W | Arm B: Vamikibart 1 mg Q8W | Arm C: Vamikibart 1 mg Q4W | Arm D: Ranibizumab 0.5 mg Q4W | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 1 | 0 | 4 |
| Asian | 5 | 6 | 5 | 6 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 6 | 6 | 6 | 28 |
| White | 36 | 45 | 49 | 50 | 180 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 42 | 43 | 37 | 38 | 160 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Dec 2021 to primary completion in Nov 2024, 34 months.
Results were first posted in May 2026, 1 year 6 months after primary completion. A results delay was requested in Oct 2025.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 34 months is above that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vamikibart